• Quest Diagnostics (NYSE:DGX) has been named to the Fortune 2026 World's Most Admired Companies list, ranking number two in its industry category.
• The company is expanding national access to Visby Medical's at-home Women's Sexual Health Test, aimed at improving rapid, confidential STI testing for women.

For investors watching NYSE:DGX, the recognition on Fortune's 2026 World's Most Admired Companies list adds a reputation angle to a stock that currently trades at $184.65. Over the past year, the share price return of 24.1% and 35.4% over three years sit alongside a 62.8% return over five years, which may catch the eye of long term holders tracking consistency.

The expanded access to at-home Women's Sexual Health Tests highlights how Quest positions itself in diagnostics and broader healthcare services. For you as an investor, it is another data point to consider when assessing how the company is pursuing opportunities and responding to public health needs.

Stay updated on the most important news stories for Quest Diagnostics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Quest Diagnostics.

For you as a shareholder or potential investor, the Fortune recognition and Visby partnership both speak to how Quest positions itself with customers and patients, which can feed into how the market views its brand strength. Being named to the World's Most Admired Companies list for the 12th consecutive year and ranking second in its industry may reinforce confidence in management, culture and customer relationships, while the at home Women's Sexual Health Test broadens Quest's reach into consumer initiated testing for a large and urgent clinical need.

Quest Diagnostics narrative, reframed by reputation and access

Quest already has an established role in diagnostic information services, and this kind of external recognition can support existing narratives that see the company as a core, long term player in U.S. healthcare infrastructure. The Visby relationship adds another angle for those watching how Quest responds to changing patient expectations around convenience, privacy and speed of testing, especially in areas like STI care where underdiagnosis has meaningful public health consequences.

Risks and rewards investors may want to weigh

• 🎁 External recognition on the Fortune list can support perceptions of quality, trust and service reliability in a competitive healthcare services space.
• 🎁 Expanded access to at home STI testing aligns Quest with a growing consumer testing channel and may strengthen its positioning in women's health.
• ⚠️ Quest faces slower revenue growth, higher costs and declining operating margins, which could limit how much value it captures from new partnerships.
• ⚠️ Eroding returns on capital suggest that not all existing profit streams are as productive as in the past, which may temper enthusiasm around new initiatives.

What to watch from here

From here, it is worth tracking how much take up Quest sees for the Visby at home offering, whether it talks about this partnership in future updates, and if recognition like the Fortune ranking coincides with any shift in investor attention. If you want to see how different investors are thinking about these developments, you can check out the community’s latest narratives by visiting this page.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.